First surgery performed in Episurf Medical’s IDE study for the Episealer® Knee implant
Episurf Medical (NASDAQ: EPIS B) today announces that the first surgery in the company's IDE Clinical Trial, EPIC-Knee: Episealer® Knee System IDE Clinical Study, was performed at a European site this morning. The first IDE-study surgery in the United States is scheduled for later in September. "We are very happy to see that these surgeries have started, and we are looking forward to presenting more about this important clinical trial at our upcoming Capital Markets Day on September 15", says Pål Ryfors, CEO Episurf Medical. For more information, please contact: Pål Ryfors,